Home » FDA Approves Fiasp for Treatment of Children With Diabetes
FDA Approves Fiasp for Treatment of Children With Diabetes
The FDA approved Novo Nordisk’s Fiasp (insulin aspart injection) 100 u/mL for use as a mealtime insulin option for children with diabetes.
The approval was based on data from a phase 3 trial of the drug’s efficacy and safety compared with conventional insulin aspart in 777 children with type 1 diabetes.
The drug is now available for use in children and adults as either multiple daily injections, continuous subcutaneous insulin infusion pumps, and infusion under supervision by a healthcare professional.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May